SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-013437
Filing Date
2022-05-10
Accepted
2022-05-10 06:06:53
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K auph-20220510.htm   iXBRL 8-K 37407
2 EX-99.1 exhibit991_q12022pressrele.htm EX-99.1 99163
6 aurinalogoa.jpg GRAPHIC 11010
  Complete submission text file 0001628280-22-013437.txt   296304

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20220510.xsd EX-101.SCH 1936
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20220510_lab.xml EX-101.LAB 23924
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20220510_pre.xml EX-101.PRE 12622
8 EXTRACTED XBRL INSTANCE DOCUMENT auph-20220510_htm.xml XML 10843
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 22907212
SIC: 2834 Pharmaceutical Preparations